



PIPER RUDNICK LLP
1200 NINETEENTH STREET, NW
WASHINGTON, DC 20036-2412
TELEPHONE: 202-861-3900
FACSIMILE: 202-223-2085

DOCKET NO.: 9511-114-27 CONT

ASSISTANT COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Re: Serial No.: 10/693,498
Applicant(s): Richard J. BUCALA, et al.
Filing Date: October 27, 2003
For: THERAPEUTIC USES OF FACTORS WHICH INHIBIT OR
NEUTRALIZE MIF ACTIVITY
Group Art Unit: 1645

SIR:

Attached hereto for filing are the following papers:

Information Disclosure Statement
List of Related Cases
PTO-1449
Cited Documents (17)

Our check in the amount of \$ 0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

PIPER RUDNICK LLP



Steven B. Kelber
Attorney of Record
Registration No.: 30,073

Patrick R. Delaney
Registration No.: 45,338

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION: Richard J. BUCALA, et al.

GROUP ART UNIT: 1645

SERIAL NUMBER: 10/693,498

EXAMINER:

FILED: October 27, 2003

FOR: THERAPEUTIC USES OF FACTORS WHICH INHIBIT OR NEUTRALIZE MIF ACTIVITY

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Assistant Commissioner for Patents
 PO BOX 1450
 ALEXANDRIA, VA 22313-1450

Sir:

Applicant(s) wish(es) to disclose the following information.

REFERENCES

- Applicant(s) wish(es) to make of record the documents listed on the attached Form PTO-1449. Copies of the listed documents were made of record in application Serial No. 08/063,399, filed May 17, 1993, now abandoned, and application Serial No. 08/243,342, filed May 16, 1994, now abandoned.

RELATED CASES

- Attached is a list of Applicant's(s') pending applications and issued patents which may be related to the present application. Copies of the documents, where required, are attached along with Form PTO-1449.

CERTIFICATION

The undersigned certifies that

- each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application for the first time (to the knowledge of the undersigned, having made reasonable inquiry) not more than three months prior to the filing of this statement.
- no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.

BASIS FOR CONSIDERATION

This Information Disclosure Statement is filed:

- without fee and within three months of the filing date of the application.
- without fee and within three months of the date of entry of the U.S. national stage.
- without fee and before the mailing date of a first Office Action on the merits (to the knowledge of the undersigned).
- without fee and with the appropriate certification above.
- without fee and with a new CPA application.
- without fee and with a Request for Continued Examination.
- with fee and before the mailing date of any of a Final Office Action, Notice of Allowance or an action that otherwise closes prosecution (to the knowledge of the undersigned).
- with fee, appropriate certification above, and before payment of the Issue Fee.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 50-1442.

Respectfully submitted,

PIPER RUDNICK LLP


 Steven B. Kelber
 Attorney of Record
 Registration No. 30,073

 Patrick R. Delaney
 Registration No. 45,338

1200 Nineteenth Street, N.W.
 Washington, DC 20036-2412
 Telephone No. (202) 861-3900
 Facsimile No. (202) 223-2085



DOCKET NO.: 9511-114-27 CONT

LIST OF RELATED CASES

Docket Number	Serial or Patent Number	Filing or Issue Date	Status or Patentee
9511-008-27	6,297,253	October 2, 2001	Granted
9511-014-27 CIP	08/738,947	October 24, 1996	Allowed
9511-018-27	6,492,428	December 10, 2002	Granted
9511-040-27	6,599,938	July 29, 2003	Granted
9511-050-27 DIV	6,645,493	November 11, 2003	Granted
9511-052-27 DIV	6,030,615	February 29, 2000	Granted
9511-069-27 DIV	6,117,837	September 12, 2000	Granted
*9511-114-27 CONT	10/693,498	October 27, 2003	Pending

The cases listed on this Notice of Related Cases include cases which may contain information that is material to patentability. The listing of a case on this Notice should not be taken as an indication or admission that any information contained therein is material. Prior art for each case listed on this Notice may have been cited. **The files corresponding to the listed cases, which are available to the Examiner, may not have not been examined to ascertain the materiality of any prior art therein.** Accordingly, the Examiner is requested to review the file for each case listed on this Notice in order to assess the materiality of such prior art.

*Present application; listed for information.

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

DOCKET NO.

9511-114-27 CONT

APPLICANT

Richard J. BUCALA, et al.

FILING DATE

October 27, 2003

LIST OF REFERENCES CITED BY APPLICANT
(Use Several Sheets if Necessary)

JUL 09 2004

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
AA	5,585,479	12/1996	HOKE, et al.	
AB	6,297,253	10/2001	BUKRINSKY, et al.	
AC	6,492,428	12/2002	AL-ABED, et al.	
AD	6,599,938	07/2003	Al-ABED, et al.	
AE	6,645,493	11/2003	BUCALA, et al.	
AF	6,030,615	02/2000	BUCALA, et al.	
AG	6,117,837	09/2000	TRACEY, et al.	
AH	4,946,778	08/1990	LADNER, et al.	
AI	4,946,674	09/1990	von EICHHORN, et al.	
AJ	4,708,937	11/1987	REMOLD	
AK	4,299,814	11/1981	BRANDT, et al.	
AE	5,411,882	05/1995	ODINK, et al.	
AM	4,683,202	07/1987	MULLIS	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
AN	WO 96/15242	05/1996	WIPO		
AQ	WO 96/09389	03/1996	WIPO		
AP	WO 95/31468	11/1995	WIPO		
AQ	WO 90/11301	10/1990	WIPO		
AR	2-219586	09/1990	JAPAN		
AS	0 162 812	11/1985	EPO		
AT	230 876	12/1985	GERMANY		

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO.	SERIAL NO.
		9511-114-27 CONT	10/693,498
		APPLICANT	
		Richard J. BUCALA, et al.	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		FILING DATE	GROUP ART UNIT
		October 27, 2003	1645

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	BA	Nathan, et al., J. Exp. Med., Vol. 133, pp. 1356-1376, 1971.
	BB	Churchill, et al., J. Immunol., Vol. 115, pp. 781-785, 1975.
	BC	McInnes, et al., J. Exp. Med., Vol. 167, pp. 598-611, 1988.
	BH	Thurman, et al., J. Immunol., Vol. 134, pp. 305-309, 1985.
	BI	Weiser, et al., Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 7522-7526, 1989.
	BJ	Weiser, et al., J. Immunol., Vol. 147, pp. 2006-2011, 1991.
	BK	Weiser, et al., Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 8049-8052, 1992.
	BL	Cuhna, et al., J. Immunol., Vol. 150, pp. 1908-1912, 1993.
	BM	Taetle, et al., Cancer Treatment Reports, Vol. 71, pp. 297-304, 1987.
	BN	Bacher, et al., Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 7849-7854, 1996.
	BO	Nature, Vol. 256, pp. 495-497, 1975.
	BP	Kosbor, et al., Immunology Today, Vol. 4, p. 72, 1983.
	BO	Cote, et al., Proc. Natl. Acad. Sci., Vol. 80, pp. 2026-2030, 1983.
	BR	Cole, et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96, 1985.
	BS	Morrison, et al., Proc. Natl. Acad. Sci., Vol. 81, pp. 6851-6855, 1984.
	BT	Rojanasakul, "Antisense oligonucleotide therapeutics: drug delivery and targeting", Advanced Drug Delivery Reviews, Vol. 18, pp. 115-131, 1996.
	BU	Gewirtz, et al., "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise", Proc. Natl. Acad. Sci., Vol. 93, pp. 3161-3163, 1996.
	BV	Branch, "A good antisense is hard to find", TIBS, Vol. 23, pp. 45-50, 1998.
	BW	Pozzi, et al., "Human recombinant migration inhibitory factor activates human macrophages to kill tumor cells", Cellular Immunology, Vol. 145, pp. 372-379, 1992.
	BX	Bennett, et al., Science, Vol. 158, pp. 80-82, 1966.
	BY	David, et al., Pathology, Vol. 56, pp. 72-77, 1966.
	BZ	Weiser, et al., J. Immunol., Vol. 126, pp. 1958-1962, 1981.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO.	SERIAL NO.
		9511-114-27 CONT	10/693,498
		APPLICANT	
		Richard J. BUCALA, et al.	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		FILING DATE	GROUP ART UNIT
		October 27, 2003	1645

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	CA	Neuberger, et al., Nature, Vol. 312, pp. 604-608, 1984.
	CB	Takeda, et al., Nature, Vol. 314, pp. 452-454, 1985.
✓	CC	Huse, et al., Science, Vol. 246, pp. 1275-1281, 1989.
✓	CD	Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, N.Y., 1989.
✓	CE	Lam, et al., Nature, Vol. 354, pp. 82-84, 1991.
✓	CF	Logan, et al., Proc. Natl. Acad. Sci. (USA), Vol. 81, pp. 3655-3659, 1984.
	CG	Mackett, et al., Proc. Natl. Acad. Sci. (USA), Vol. 79, pp. 7415-7419, 1982.
	CH	Mackett, et al., J. Virol., Vol. 49, pp. 857-864, 1984.
	CI	Panicali, et al., Proc. Natl. Acad. Sci., Vol. 79, pp. 4927-4931, 1982.
	CJ	Uhlmann, et al., "Antisense oligonucleotides: A new therapeutic principle", Chemical Reviews, Vol. 90, No. 4, pp. 543-584, 1990.
	CK	Stein, et al., Science, Vol. 261, pp. 1004-1012, 1993.
	CL	Kohler, et al., Nature, Vol. 256, pp. 495-497, 1975.
	CM	Kaiser, et al., Proc. Natl. Acad. Sci. USA, Vol. 80, pp. 1137-1143, 1983.
	CN	Peck, J. Immunol. Methods, Vol. 64, pp. 179-187, 1983.
	CO	Sprung, et al., New Eng. Eng. J. Med., Vol. 317, pp. 1137-1143, 1984.
	CP	Beutler, et al., J. Exp. Med., Vol. 161, pp. 984-995, 1985.
	CQ	Erne, et al., Biochemistry, Vol. 24, pp. 4263-4265, 1985.
	CR	Beutler, et al., J. Immunol., Vol. 135, pp. 3972-3977, 1985.
	CS	Suzuki, et al., Am. J. Physiol., Vol. 250, pp. E470-E474, 1986.
	CT	Liu, et al., J. Immunol., Vol. 137, pp. 448-455, 1986.
	CU	Thomas, et al., Cell, Vol. 51, pp. 503-512, 1987.
	CV	Bone, et al., New Eng. J. Med., Vol. 311, pp. 1137-1141, 1987.
	CW	Ding, et al., J. Immunol., Vol. 141, pp. 2407-2413, 1988.
	CX	Smith, Science, Vol. 240, pp. 1169-1176, 1988.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO.	SERIAL NO.
		9511-114-27 CONT	10/693,498
		APPLICANT	
		Richard J. BUCALA, et al.	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		FILING DATE	GROUP ART UNIT
		October 27, 2003	1645

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	DA	Michie, et al., New Eng. J. Med., Vol. 318, pp. 1481-1486, 1988.
	DB	Wolpe, et al., J. Exp. Medicine, Vol. 167, pp. 570-581, 1988.
	DC	Sternberg, et al., Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 2374-2378, 1989.
	DD	Zuckerman, et al., Eur. J. Immunol., Vol. 19, pp. 301-305, 1989.
	DE	Buhler, et al., Biotechnology, Vol. 8, pp. 140-143, 1990.
	DF	Edwards III, et al., Endocrinol., Vol. 128, pp. 986-989, 1991.
	DG	Dinarello, J. Infect. Dis., Vol. 163, pp. 1177-1184, 1991.
	DH	Edwards III, et al., Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 2274-2277, 1991.
	DI	Silverstein, et al., J. Exp. Med., Vol. 173, pp. 357-365, 1991.
	DI	Holmes, et al., Science, Vol. 253, pp. 1278-1280, 1991.
	DK	Fry, et al., Biopolymers, Vol. 32, pp. 649-666, 1992.
	DL	Sigal, et al., Ann. Rev. Immunol., Vol. 10, pp. 519-560, 1992.
	DM	Blocki, et al., Nature, Vol. 360, pp. 269-270, 1992.
	DN	Vassalli, Ann. Rev. Immunol., Vol. 10, pp. 411-452, 1992.
	DO	Fung-Leung, et al., Cell, Vol. 65, pp. 443-449, 1991.
	DP	Lanahan, et al., Mol. Cell Biol., Vol. 12, pp. 3919-3929, 1992.
	DQ	Sherry, et al., Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 3511-3515, 1992.
	DR	Bernhagen, et al., J. Cell Biochem. Supplement 178, Abstract E306, 1993.
	DS	Wistow, et al., Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 1272-1275, 1993.
	DT	Bernhagen, et al., Nature, Vol. 365, pp. 756-759, 1993.
	DU	Mikayama et al., Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 10056-10060, 1993.
	DV	Nathan, et al., J. Exp. Med., Vol. 137, pp. 275-288, 1973./
	DW	Nathanson, et al., Annals of Internal Medicine, Vol. 120, pp. 771-783, 1994.
	DX	The Merck Manual of Diagnosis and Therapy, Berkow, Editor-in-Chief, Merck Research Laboratories, Publisher, Sixteenth Edition, pp. 318-319, 338-388, and 1305-1311, 1992.
	DY	Immunology, Kuby, Freeman and Co., Publisher, p. 266, 1992.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.